文献速递冠心病血脂与心血管预防

低剂量秋水仙碱治疗动脉粥样硬化:长期安全性

Low-dose colchicine for atherosclerosis: long-term safety.
PubMed 文献 · Eur Heart J · 2024-01-01

本文汇总病例报告系统评价、药物注册研究和安慰剂对照试验数据,评估连续使用低剂量秋水仙碱(0.5 mg/日)在多种临床场景中的安全性,包括他汀治疗者。结论认为,除初期轻度腹泻多在一周内消退外,连续使用耐受良好且非常安全,不增加癌症、严重感染或特定原因死亡风险。

要点

  • 低剂量秋水仙碱(0.5 mg/日)连续使用总体耐受良好且非常安全。
  • 初期轻度腹泻多在一周内消退,不影响肾、肝或认知功能。
  • 无显著肾或肝损害者,骨髓抑制、肌毒性和严重药物相互作用罕见且不高于安慰剂。

核心结论

  • 在无显著肾或肝损害的患者中,连续使用低剂量秋水仙碱可安全用于动脉粥样硬化患者以降低心血管风险。

研究设计与样本

  • 本综述汇总了病例报告系统评价、药物注册研究和安慰剂对照试验的数据,评估低剂量秋水仙碱(0.5 mg/日)连续使用的安全性。

主要发现

  • 初期轻度腹泻通常在治疗一周内消退。
  • 连续使用低剂量秋水仙碱不影响肾、肝或认知功能。
  • 对出血、伤口愈合、生育或妊娠无不良影响。
  • 不增加癌症、严重感染或特定原因死亡的风险。
  • 在无显著肾或肝损害者中,骨髓抑制、肌毒性和严重药物相互作用报告罕见且不高于安慰剂,包括他汀治疗者。

关键数值与推荐

  • 低剂量秋水仙碱剂量为0.5 mg每日一次。
  • 适用于无显著肾或肝损害的患者。

临床怎么用

  • 医生、药师和患者可放心,在无显著肾或肝损害时连续使用低剂量秋水仙碱安全性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Low-dose colchicine (0.5 mg daily) is now FDA-approved for secondary prevention in patients with coronary disease and will be increasingly prescribed in clinical practice. In this State-of-the-Art Review, data were collated from contemporary systemic reviews of case reports, drug registries, and placebo-controlled trials that assessed specific issues of safety related to the continuous use of colchicine in a range of clinical settings to inform physicians, pharmacists, and patients of the absolute risks of continuous use of low-dose colchicine, including among individuals taking statin therapy. Based upon these collective data, it is concluded that aside mild diarrhoea on initiation of colchicine that typically subsides in the vast majority of patients within a week of therapy, continuous use of low-dose colchicine is well tolerated and very safe. It does not affect renal, liver, or cognitive function, has no adverse effects on bleeding, wound healing, fertility, or pregnancy, and does not increase risks of cancer, serious infection, or cause-specific mortality. When appropriately prescribed to patients without significant renal or hepatic impairment, reports of myelosuppression, myotoxicity, and serious drug-drug interactions are rare and no more frequent than placebo, including in patients taking statin therapy. Physicians, pharmacists, and patients can be reassured that in the absence of significant renal or hepatic impairment continuous use of low-dose colchicine can be used safely in patients with atherosclerosis for the purpose of reducing cardiovascular risk.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Nidorf SM, Ben-Chetrit E, Ridker PM, et al. Low-dose colchicine for atherosclerosis: long-term safety. Eur Heart J. 2024. PMID: 38596868. doi:10.1093/eurheartj/ehae208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。